Role of Adenosine Receptors in Rare Neurodegenerative Diseases with Motor Symptoms

Curr Protein Pept Sci. 2021 Sep 9. doi: 10.2174/1389203722666210910110126. Online ahead of print.ABSTRACTThe approval of istradefylline, an adenosine 2A receptor (A2AR) antagonist, as an add-on treatment in adult patients with Parkinson's disease by the Food and Drug Administration (FDA) and European Medicines Agency (EMA), is the latest proof of the importance of the adenosinergic system in the nervous system. Adenosine is an endogenous purine nucleoside with a role as a modulator of both neurotransmission and the inflammatory response. As such, the expression pattern of the 4 adenosine receptors (A1R, A2AR, A2BR and A3R) and the extracellular adenosine levels have attracted great interest in the pathogenesis and possible treatment of rare neurodegenerative diseases with motor symptoms. These include Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), restless legs syndrome (RLS) and Machado-Joseph disease (MJD, also known as spinocerebellar ataxia type 3, SCA3). In this review, we shall focus on the role of the different adenosine receptor subtypes in the development and possible treatment of the aforementioned rare neurodegenerative diseases with motor symptoms using the currently available data. The last section discusses the possibility of a role for the adenosine receptors in the treatment of other rare diseases based on the available molecular pathology knowledge.PMID:34514988 | DOI:10.2174/1389203722666210910110126
Source: Current Protein and Peptide Science - Category: Biochemistry Authors: Source Type: research

Related Links:

We describe a patient with psoriasis, psoriatic arthritis and uveitis who was treated with adalimum ab and after 4 months of the treatment developed clinical and neuroradiological signs of demyelinating disease of the central nervous system. She experienced no signs and symptoms of neurological disease prior to adalimumab administration. After a detailed neurological work-up she was diagnosed wit h relapsing–remitting type of multiple sclerosis and treated with oral and pulse glucocorticoids and later with dimethyl fumarate. Adalimumab was discontinued. The question remains was the demyelination induced by the T...
Source: Rheumatology International - Category: Rheumatology Source Type: research
ConclusionWe experienced successful treatment for an inoperable case of desmoid-type fibromatosis with hydronephrosis. Moderate-dose radiation therapy alone is an effective and feasible approach for the management of hydronephrosis associated with desmoid-type fibromatosis.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
A popular antipsychotic calms patients with multiple sclerosis (MS) who develop psychiatric distress after taking corticosteroids, a new case review suggests.Medscape Medical News
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
In conclusion, mitophagy pathways play an important role in maintaining physiological homeostasis, are involved in the mechanisms of aging and neurodegenerative disorders, and represent promising targets for the development of potential therapeutic agents aimed at regulating mitochondria quality control in neurons and glial cells. A significant number of molecules that induce or inhibit mitophagy are currently under consideration, which may be useful for testing hypotheses or developing drugs for the treatment of neurodegenerative diseases. The validation of promising drugs in animal and cell models, including neurons and ...
Source: Fight Aging! - Category: Research Authors: Tags: Medicine, Biotech, Research Source Type: blogs
This article is licensed under aCreative Commons Attribution 3.0 Unported Licence.Ryan Limbocker, Silvia Errico, Denise Barbut, Tuomas P. J. Knowles, Michele Vendruscolo, Fabrizio Chiti, Michael Zasloff The natural products squalamine and trodusquemine are promising potential therapeutics against Alzheimer's, Parkinson's, and other neurodegenerative diseases for their ability to modulate protein aggregation processes and target protein misfolded oligomers that are toxic to neurons. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Nat. Prod. Rep. latest articles - Category: Chemistry Authors: Source Type: research
Condition:   Parkinson Disease Intervention:   Other: No intervention will be offered Sponsors:   The Hong Kong Polytechnic University;   Chinese University of Hong Kong;   The University of Hong Kong;   Parkinson's Disease Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Curr Protein Pept Sci. 2021 Sep 9. doi: 10.2174/1389203722666210910110126. Online ahead of print.ABSTRACTThe approval of istradefylline, an adenosine 2A receptor (A2AR) antagonist, as an add-on treatment in adult patients with Parkinson's disease by the Food and Drug Administration (FDA) and European Medicines Agency (EMA), is the latest proof of the importance of the adenosinergic system in the nervous system. Adenosine is an endogenous purine nucleoside with a role as a modulator of both neurotransmission and the inflammatory response. As such, the expression pattern of the 4 adenosine receptors (A1R, A2AR, A2BR and A3R)...
Source: Current Protein and Peptide Science - Category: Biochemistry Authors: Source Type: research
More News: ALS | Ataxia | Biochemistry | Brain | European Medicines Agency (EMA) | Food and Drug Administration (FDA) | Huntington's Disease | Multiple Sclerosis | Neurology | Neuroscience | Parkinson's Disease | Pathology | Rare Diseases | Restless Legs Syndrome | Science